Concord Medical Services (ADR) (CCM)
Provides oncology care, radiotherapy infrastructure, and cloud services across China.
Something off on this page? Send us feedback.
Delivers outpatient and inpatient oncology care through self-owned Chinese institutions while supplying equipment, management, and cloud services to partner hospitals. Most revenue comes from the hospital segment, and the NYSE-listed parent consolidates separately listed Concord Healthcare through delegated voting rights.
Provides oncology care through self-owned hospitals, clinics, and an imaging center in China, with Guangzhou Hospital offering diagnostic imaging, radiation therapy, chemotherapy, interventional radiology, targeted therapy, immunotherapy, and surgery. The portfolio also includes Shanghai outpatient and imaging facilities plus an internet hospital for follow-up health management.
Runs a separate network business that supplies and leases medical equipment, manages cooperative radiotherapy and imaging centers, and sells technical support and Jiahe cloud services. Partner arrangements combine equipment provision with revenue sharing, while self-owned institutions bill patients and public or commercial payers.
Operations are concentrated in China and depend on medical-equipment quotas, clinical and institutional permits, insurance-pricing rules, hospital partners, qualified clinicians, referral flows, and limited equipment suppliers. Parent reporting currently consolidates separately listed Concord Healthcare through delegated voting rights, a status under review following its board changes.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $44.3M · Total debt $541.1M · Total assets $974.6M · Shareholders' equity −$313.0M
- Revenue
- $38.0M
- Operating income
- −$13.8M
- Net income
- −$9.6M
Reported in CNY, converted at the latest exchange rate
No dividends on record.
| Institutions1 holder · as of Sep 30, 2025 | 0.01% | 440 ADS | |
| Insiders3 holders · as of Jul 9, 2026 | 7.72% | 670.1K ADS | |
| Otherremainder | 92.27% | 8.01M ADS |
8.68M ADS (1 ADS = 3 ordinary shares) as of Sep 3, 2026 · institutions as of Sep 30, 2025 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
This company has 3 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Jianyu YangInsiderdirector, officer: Chief Executive Officer | 5.37% | 466,097 ADS | Form 4filed Mar 18, 2026 ↗ |
Botao ShiInsiderofficer: Interim CFO | 1.83% | 477,000 A ordinary | Form 4filed Jul 9, 2026 ↗ |
Liping ZhangInsiderdirector | 0.52% | 135,000 A ordinary | Form 4filed Mar 18, 2026 ↗ |
Eversource Wealth Advisors, LLCInstitution | 0.01% | 440 ADS | 13Fas of Sep 30, 2025 |
Zheng ChengInsiderdirector | 0.00% | 0 | Form 4filed Mar 18, 2026 ↗ |
| See all 6 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
Not reported.